2 minute explanation
Cleveland Clinic: pelacarsen did not cut CV events in Lp(a)HORIZON (12.3% vs 12.1%)
Louis shares the Cleveland Clinic press release on Lp(a)HORIZON, a 797-site randomized trial in 8,322 patients with prior CVD and Lp(a) of at least 70 mg/dL. The primary endpoint occurred in 12.3% on pelacarsen versus 12.1% on placebo after a median 57 months. Senior author Steven Nissen said a single neutral trial does not prove lack of benefit from lowering Lp(a).
▶
